Company: STAA
Filing Date: 2025-09-16
Form Type: DEFM14A
Source: 0001193125-25-204396
Chunk: 133

Company: STAAR SURGICAL CO
Filing Date: 2025-09-16
Form: DEFM14A
Chunk 133
---
 the Exchange Agent, together with such letter of transmittal, duly executed and properly completed and such other documents as may be reasonably requested by the Exchange Agent, the holder of such Certificate or Book-Entry Share will be entitled
to receive in exchange therefor the Merger Consideration (such payments to be net of applicable taxes withheld) for each share of STAAR common stock formerly represented by such Certificate or Book-Entry Share, and the Certificate or Book-Entry
Share so surrendered will forthwith be canceled.

At any time following twelve (12) months after the Effective Time, Alcon may
require the Exchange Agent to deliver to it any unclaimed funds, at which point holders of shares entitled to the unclaimed funds may look only to the Surviving Corporation (subject to abandoned property, escheat, or other similar laws) only as
general creditors with respect to the Merger Consideration payable upon due surrender of their certificates or shares of STAAR common stock, without any interest thereon.

-79-

Representations and Warranties The Merger Agreement contains representations and warranties of STAAR, Alcon, and Merger Sub. Some of the representations and warranties in the Merger Agreement made by STAAR are qualified as to “materiality” or “Material Adverse Effect.” For purposes of the Merger Agreement, a “Material Adverse Effect” means any event, occurrence, circumstance, change, or effect which, individually or when taken together with all other events, occurrences, circumstances, changes or effects, has had or would reasonably be expected to have a material adverse effect on the business, assets, financial condition or results of operations of STAAR and its subsidiaries, taken as a whole; provided, however, that none of the following will be deemed to constitute or be taken into account in determining whether there has been, or would reasonably be expected to be, a Material Adverse Effect:

| (i) | any change in the market price or trading volume of shares of STAAR common stock or change in STAAR’s                                                                                                                                      
 credit ratings (provided that the underlying causes of any such change may be considered in determining whether a Material Adverse Effect has occurred to the extent not otherwise excluded by another exception in the Merger Agreement); |

| (ii) | any event, occurrence, circumstance, change, or effect resulting from the execution, announcement, pendency, or                                                                                                                                     
 performance of the transactions contemplated by the Merger Agreement, including any impact on the relationships of STAAR and its subsidiaries with employees,